BioNotebook: Deals from Five Prime/GSK, Actavis/Rhythm, Apricus/Forendo; a DARPA collaboration and IPO news
This article was originally published in Scrip
Five Prime, GSK expand collaboration; Actavis gains option to buy Rhythm subsidiary; Apricus licenses fispemifene from Forendo; Inovio, MedImmune partner with DARPA money; and IPO updates from DBV, Coherus, S1 Biopharma and Tobira.
You may also be interested in...
Emerging Company Profile: Finland's Forendo Pharma hopes an imminent improvement in diagnostic possibilities will eventually help it commercialize a drug for endometriosis, which it believes could enable more effective treatment of a disease that afflicts large numbers of women.
Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.
As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?